U.S. Food and Drug Administration has amended the emergency use authorization for the Pfizer COVID-19 Vaccine

The U.S. Food and Drug Administration amended the emergency use authorization for the Pfizer COVID-19 Vaccine to allow for use of a single booster dose, to be administered at least six months after completion of the primary series. The booster dose is for people who are 65 and older, those aged 18 to 64 at high risk of severe Covid 19, and those who are frequently exposed and are at high risk for serious complications of COVID-19.